IJMABHR International Journal of Medical and All Body Health ResearchIJMABHR 2582-8940 Anfo Publication House 469 Reversal of Neuromuscular Blockade: A Comparative Study of Neostigmine Versus Sugammadex SinghPushpendra Neeraj BhatImtiyaz Ahmad G.S. Medical College and Hospital, Hapur, Uttar Pradesh, India 01052026 7 2 89 100 03032026 02042026 CC BY-NC-SA 4.0

Background: Neuromuscular blocking agents (NMBAs) are essential in modern anesthesia, but inadequate reversal leads to residual neuromuscular blockade (RNMB), causing significant postoperative complications. This study compares the efficacy, safety, and clinical outcomes of neostigmine and sugammadex for reversal of neuromuscular blockade. Methods: A comprehensive review of randomized controlled trials and observational studies comparing neostigmine and sugammadex was conducted. Primary outcomes included time to reversal, incidence of RNMB, and postoperative complications. Secondary outcomes examined hemodynamic stability, adverse effects, and cost-effectiveness. Results: Sugammadex demonstrated significantly faster reversal times across all depths of blockade compared to neostigmine. The incidence of RNMB was markedly lower with sugammadex (2-5%) versus neostigmine (15-40%). Sugammadex showed superior safety profile with fewer cardiovascular and muscarinic side effects. Conclusions: Sugammadex offers superior efficacy and safety compared to neostigmine for reversal of neuromuscular blockade, particularly in deep blockade scenarios. Despite higher acquisition costs, improved outcomes and reduced complications support its clinical adoption.

 Neuromuscular blockadesugammadexneostigmineresidual paralysisanesthesia reversal References Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology. 1942;3(4):418-420. Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2020;125(5):655-660. Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia. 2017;72(Suppl 1):16-37. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111(1):120-128. Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans. Anesthesiology. 1997;87(5):1035-1043. Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. Acta Anaesthesiol Scand. 1997;41(9):1095-1103. Baillard C, Clec'h C, Catineau J, et al. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth. 2005;95(5):622-626. Norton M, Ackermann G, Cunning E, et al. Prevalence and recognition of post -operative residual neuromuscular block in a post anesthesia care unit using qualitative train of four monitoring. J Anesth Clin Res. 2013;4:305. Miller RD, Ward TA. Monitoring and pharmacologic reversal of neuromuscular blockade. In: Miller RD, editor. Miller's Anesthesia. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 1001-1025. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 175-191. Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia. 2009;64(Suppl 1):22-30. American Society of Anesthesiologists; Thilen SR, Weigel WA, Todd MM, et al. 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade. Anesthesiology. 2023;138(1):13-41. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed. 2002;41(2):265-270. Naguib M. Sugammadex: another milestone in clinical International Journal of Medical and All Body Health Research www.allmedicaljournal.com neuromuscular pharmacology. Anesth Analg. 2007;104(3):575-581. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology. 2006;104(4):667-674. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003;99(3):632-637. Bevan DR, Donati F, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology. 1992;77(4):785-805. Bowman WC. Neuromuscular block. Br J Pharmacol. 2006;147(Suppl 1):S277-S286. Mirakhur RK, Dundee JW, Jones CJ, Coppel DL, Clarke RS. Reversal of neuromuscular blockade: dose determination studies with atropine and glycopyrronium bromide. Anaesthesia. 1981;36(10):983-986. Kopman AF. Neostigmine. Anesthesiology. 2004;100(4):1020-1024. Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology. 2002;96(1):202-231. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98(5):1042-1048. Welliver M, McDonough J, Kalynych N, Redfern R. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. Drug Des Devel Ther. 2008;2:49-59. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex sodium: a selective relaxant binding agent for the reversal of neuromuscular blockade. J Pharmacol Exp Ther. 2007;321(1):217-224. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium -induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007;106(5):935-943. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106(2):283-288. Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109(2):188-197. Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009;110(5):1020-1025. Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107(1):130-137. Eikermann M, Groeben H, Hüsing J, Peters J. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. Anesthesiology. 2003;98(6):1333-1337. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans. Anesthesiology. 2000;92(4):977-984. Murphy GS, Szokol JW, Avram MJ, et al. Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology. 2011;115(5):946-954. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345:e6329. Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006;102(2):426-429.